Patents by Inventor Kenneth Santora

Kenneth Santora has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins
    Patent number: 7470775
    Abstract: CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making disulfide stabilized Fv (“dsFv”)-immunoconjugates. The dsFv immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: December 30, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira H. Pastan, Satoshi Nagata, Masanori Onda, Yoshito Numata, Kenneth Santora, Richard Beers, Robert Kreitman, Abhishek Sinha
  • Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins
    Publication number: 20060193771
    Abstract: CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making disulfide stabilized Fv (“dsFv”)-immunoconjugates. The dsFv immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.
    Type: Application
    Filed: June 11, 2003
    Publication date: August 31, 2006
    Inventors: Ira Pastan, Satoshi Nagata, Masanori Onda, Yoshito Numata, Kenneth Santora, Richard Beers, Robert Kreitman, Abhishek Sinha